A drug discovery bottleneck? How cheaper reagents could speed branched molecule synthesis

When chemists design drug candidates, shape matters enormously. Many active pharmaceutical ingredients contain branched carbon structures—points where the molecular chain forks in a specific direction—that are critical to whether a molecule will bind to its biological target and whether it will be safe. The challenge is that the branched building blocks used to create these structures are not very abundant or commercially available. Now, scientists at Scripps Research have devised a new approach to building these branched molecular structures found in many medicines and materials: one that could make the early stages of drug discovery faster and more efficient.